Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Nov, 2016 | Pages:
109 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Acute Coronary Syndrome - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Acute Coronary Syndrome - Pipeline Review, H2 2016, provides an overview of the Acute Coronary Syndrome (Cardiovascular) pipeline landscape. Acute coronary syndrome is a term used for conditions brought on by sudden, reduced blood flow to the heart. Symptoms include chest pain, pain elsewhere in the body, such as the left upper arm or jaw, nausea, vomiting and shortness of breath. Risk factors include age, high blood pressure, high blood cholesterol, cigarette smoking and Type 2 diabetes. Treatment includes beta blockers, calcium channel blockers, cholesterol-lowering drugs and angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBS). Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Acute Coronary Syndrome - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Acute Coronary Syndrome (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Acute Coronary Syndrome (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Acute Coronary Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 6, 3, 9 and 1 respectively.Acute Coronary Syndrome. Acute Coronary Syndrome (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Acute Coronary Syndrome (Cardiovascular). - The pipeline guide reviews pipeline therapeutics for Acute Coronary Syndrome (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Acute Coronary Syndrome (Cardiovascular) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Acute Coronary Syndrome (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Acute Coronary Syndrome (Cardiovascular) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Acute Coronary Syndrome (Cardiovascular). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Acute Coronary Syndrome (Cardiovascular) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Acute Coronary Syndrome Overview 8 Therapeutics Development 9 Pipeline Products for Acute Coronary Syndrome - Overview 9 Acute Coronary Syndrome - Therapeutics under Development by Companies 10 Acute Coronary Syndrome - Pipeline Products Glance 11 Late Stage Products 11 Clinical Stage Products 12 Early Stage Products 13 Acute Coronary Syndrome - Products under Development by Companies 14 Acute Coronary Syndrome - Companies Involved in Therapeutics Development 15 advanceCor GmbH 15 Arena Pharmaceuticals, Inc. 16 Ascendia Pharmaceuticals LLC 17 Athera Biotechnologies AB 18 Bayer AG 19 Cardiome Pharma Corp. 20 Cerenis Therapeutics Holding SA 21 CSL Limited 22 Esperion Therapeutics, Inc. 23 HitGen LTD 24 Japan Tobacco Inc. 25 Lee's Pharmaceutical Holdings Limited 26 LipimetiX Development Inc 27 MedImmune LLC 28 Pfizer Inc. 29 The Medicines Company 30 Verseon Corporation 31 Acute Coronary Syndrome - Therapeutics Assessment 32 Assessment by Monotherapy Products 32 Assessment by Target 33 Assessment by Mechanism of Action 35 Assessment by Route of Administration 37 Assessment by Molecule Type 39 Drug Profiles 41 4-WF - Drug Profile 41 Product Description 41 Mechanism Of Action 41 R&D Progress 41 AEM-28 - Drug Profile 42 Product Description 42 Mechanism Of Action 42 R&D Progress 42 AEM-2802 - Drug Profile 44 Product Description 44 Mechanism Of Action 44 R&D Progress 44 Biologics for Acute Coronary Syndrome - Drug Profile 45 Product Description 45 Mechanism Of Action 45 R&D Progress 45 CER-001 - Drug Profile 46 Product Description 46 Mechanism Of Action 46 R&D Progress 46 clopidogrel bisulphate - Drug Profile 50 Product Description 50 Mechanism Of Action 50 R&D Progress 50 COR-2 - Drug Profile 51 Product Description 51 Mechanism Of Action 51 R&D Progress 51 CSL-112 - Drug Profile 52 Product Description 52 Mechanism Of Action 52 R&D Progress 52 dalcetrapib - Drug Profile 54 Product Description 54 Mechanism Of Action 54 R&D Progress 54 MDCO-216 - Drug Profile 58 Product Description 58 Mechanism Of Action 58 R&D Progress 58 MEDI-6012 - Drug Profile 61 Product Description 61 Mechanism Of Action 61 R&D Progress 61 PC-mAb - Drug Profile 63 Product Description 63 Mechanism Of Action 63 R&D Progress 63 PF-06282999 - Drug Profile 65 Product Description 65 Mechanism Of Action 65 R&D Progress 65 PMC-6 - Drug Profile 66 Product Description 66 Mechanism Of Action 66 R&D Progress 66 PR-15 - Drug Profile 67 Product Description 67 Mechanism Of Action 67 R&D Progress 67 rivaroxaban - Drug Profile 69 Product Description 69 Mechanism Of Action 69 R&D Progress 69 Small Molecules to Inhibit PCSK9 for Acute Coronary Syndrome and Atherosclerosis - Drug Profile 83 Product Description 83 Mechanism Of Action 83 R&D Progress 83 Small Molecules to Inhibit Thrombin for Cardiovascular Diseases - Drug Profile 84 Product Description 84 Mechanism Of Action 84 R&D Progress 84 temanogrel hydrochloride - Drug Profile 85 Product Description 85 Mechanism Of Action 85 R&D Progress 85 tirofiban hydrochloride - Drug Profile 87 Product Description 87 Mechanism Of Action 87 R&D Progress 87 ZK-001 - Drug Profile 88 Product Description 88 Mechanism Of Action 88 R&D Progress 88 Acute Coronary Syndrome - Dormant Projects 90 Acute Coronary Syndrome - Discontinued Products 92 Acute Coronary Syndrome - Product Development Milestones 94 Featured News & Press Releases 94 Sep 01, 2016: FDA Approves New AGGRASTAT Product Format 94 Aug 30, 2016: Completion of patient enrolment in the CARAT study - meeting the clinical schedule 94 Aug 23, 2016: DalCor Announces Opening of International Trial Sites for Its Dal-GenE Phase 3 Cardiovascular Outcomes Trial 95 Jul 18, 2016: DalCor Dalcetrapib Demonstrates Genotype-Dependent Effects on Cholesterol Efflux and Inflammation in Data Published by The Montreal Heart Institute in Circulation: Cardiovascular Genetics 96 Jul 07, 2016: Medicure Receives Response Letter from FDA on AGGRASTAT sNDA for New Indication 97 May 11, 2016: Medicure Files Application for New AGGRASTAT Product Format 98 Apr 26, 2016: DalCor Randomizes First Patient in the DalGenE Phase 3 Cardiovascular Outcomes Trial 98 Apr 25, 2016: Patent Term for Rivaroxaban Extended in US 99 Dec 14, 2015: The Medicines Company Announces Investigational Lipid Modulating Agent, MDCO-216, Phase 1 Data Published in European Heart Journal- Cardiovascular Pharmacotherapy 101 Nov 10, 2015: Cerenis Therapeutics: New Data for CER-001 Presented in Key Oral Session at American Heart Association Conference 2015 103 Sep 08, 2015: First patients enter phase II CARAT trial to assess reduction in atherosclerotic plaque using CER-001 in post Acute Coronary Syndrome (ACS) patients 103 Jul 23, 2015: Capstone Therapeutics Announces Patent Application for Novel, More Potent Chimeric Apo E Mimetic Peptides 104 Jun 08, 2015: DalCor Pharma licenses a late-stage investigational cardiovascular drug following major scientific discovery 105 May 11, 2015: Xarelto Bleeding Lawsuit Judge Orders the Selection of Cases for Discovery, Reports Xarelto Lawsuit Funding Firm, Fair Rate Funding 106 Appendix 108 Methodology 108 Coverage 108 Secondary Research 108 Primary Research 108 Expert Panel Validation 108 Contact Us 108 Disclaimer 109
List of Tables Number of Products under Development for Acute Coronary Syndrome, H2 2016 9 Number of Products under Development by Companies, H2 2016 10 Comparative Analysis by Late Stage Development, H2 2016 11 Comparative Analysis by Clinical Stage Development, H2 2016 12 Comparative Analysis by Early Stage Development, H2 2016 13 Products under Development by Companies, H2 2016 14 Acute Coronary Syndrome - Pipeline by advanceCor GmbH, H2 2016 15 Acute Coronary Syndrome - Pipeline by Arena Pharmaceuticals, Inc., H2 2016 16 Acute Coronary Syndrome - Pipeline by Ascendia Pharmaceuticals LLC, H2 2016 17 Acute Coronary Syndrome - Pipeline by Athera Biotechnologies AB, H2 2016 18 Acute Coronary Syndrome - Pipeline by Bayer AG, H2 2016 19 Acute Coronary Syndrome - Pipeline by Cardiome Pharma Corp., H2 2016 20 Acute Coronary Syndrome - Pipeline by Cerenis Therapeutics Holding SA, H2 2016 21 Acute Coronary Syndrome - Pipeline by CSL Limited, H2 2016 22 Acute Coronary Syndrome - Pipeline by Esperion Therapeutics, Inc., H2 2016 23 Acute Coronary Syndrome - Pipeline by HitGen LTD, H2 2016 24 Acute Coronary Syndrome - Pipeline by Japan Tobacco Inc., H2 2016 25 Acute Coronary Syndrome - Pipeline by Lee's Pharmaceutical Holdings Limited, H2 2016 26 Acute Coronary Syndrome - Pipeline by LipimetiX Development Inc, H2 2016 27 Acute Coronary Syndrome - Pipeline by MedImmune LLC, H2 2016 28 Acute Coronary Syndrome - Pipeline by Pfizer Inc., H2 2016 29 Acute Coronary Syndrome - Pipeline by The Medicines Company, H2 2016 30 Acute Coronary Syndrome - Pipeline by Verseon Corporation, H2 2016 31 Assessment by Monotherapy Products, H2 2016 32 Number of Products by Stage and Target, H2 2016 34 Number of Products by Stage and Mechanism of Action, H2 2016 36 Number of Products by Stage and Route of Administration, H2 2016 38 Number of Products by Stage and Molecule Type, H2 2016 40 Acute Coronary Syndrome - Dormant Projects, H2 2016 90 Acute Coronary Syndrome - Dormant Projects (Contd..1), H2 2016 91 Acute Coronary Syndrome - Discontinued Products, H2 2016 92 Acute Coronary Syndrome - Discontinued Products (Contd..1), H2 2016 93
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
